In silico modeling of combination systemic therapy for advanced renal cell carcinoma

Therapeutic combinations of VEGFR tyrosine kinase inhibitor plus immune checkpoint blockade now represent a standard in the first-line management of patients with advanced renal cell carcinoma. Tumor molecular profiling has shown notable heterogeneity when it comes to activation states of relevant p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotecha, Ritesh R, Hsu, Dennis J, Lee, Chung-Han, Patil, Sujata, Voss, Martin H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710908/
https://www.ncbi.nlm.nih.gov/pubmed/34952852
http://dx.doi.org/10.1136/jitc-2021-004059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710908/
https://www.ncbi.nlm.nih.gov/pubmed/34952852
http://dx.doi.org/10.1136/jitc-2021-004059

Ejemplares similares